Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
rivastigmine hydrogen tartrate, Quantity: 9.6 mg
Arrotex Pharmaceuticals Pty Ltd
rivastigmine hydrogen tartrate
Capsule
Excipient Ingredients: maize starch; microcrystalline cellulose; Gelatin; iron oxide red; stearic acid; titanium dioxide; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide
Oral
112, 28, 56, 14
(S4) Prescription Only Medicine
Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type
Visual Identification: Hard gelatine calsule with orange, opaque body and red opaque cap. Imprinted "APO R6" in black ink, white to off white fill.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2010-07-27